In the phase 3 COBRA trial, the carfilzomib/lenalidomide/dexamethasone regimen shows significant improvements in PFS and other outcomes in newly diagnosed MM, including in patients at cytogenic risk.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/carfilzomib-improves-upon-bortezomib-multiple-myeloma-2025a1000yn9?src=rss
Author :
Publish date : 2025-12-10 12:41:00
Copyright for syndicated content belongs to the linked Source.